药品关税的"什么"是什么:所有临床医生应该知道的
Leslie S Fish1, Nicholas Doyle1, Jerry H Gurwitz2
1IPD Analytics, Aventura, FL, USA.
Journal of general internal medicine
|November 12, 2025
概括
美国对制药品征收关税可能会增加药品成本,导致药品短缺. 药品免征关税对于患者的获取,负担能力和安全至关重要,需要临床医生意识到贸易政策的影响.
科学领域:
- 卫生政策 卫生政策
- 制药经济学 制药经济学
- 供应链管理 供应链管理
背景情况:
- 美国严重依赖全球药品和活性药物成分 (API) 供应链.
- 特朗普政府对进口药品提出的关税对医疗保健系统,提供者和患者构成重大风险.
- 仿制药制造商以微薄的利率运作,特别容易受到关税带来的财务不可持续性影响,这可能导致产品停止销售.
研究的目的:
- 分析药品关税对美国医疗保健系统,药品负担能力和患者获取的影响.
- 评估贸易政策对药物供应和患者护理的潜在影响.
- 倡导药品免征关税,以确保医疗保健系统的稳定性和患者的福祉.
主要方法:
- 这一观点分析了拟议的制药关税对经济和后勤的影响.
- 它检查了不同市场部分 (品牌与通用药) 对成本增加的脆弱性.
- 该分析考虑了将国内制药制造业重新出口的长期挑战.
主要成果:
- 关税可能会导致药品成本增加和供应链脆弱性导致药品短缺.
- 患者可能会面临更高的自付费用,有限的配方药和增加的不遵守.
- 扩大国内制造业是一个长期目标,需要大量的投资和时间.
结论:
- 从关税中豁免药品对于保持药物的负担能力,可获得性和安全至关重要.
- 临床医生必须了解贸易政策对药物可用性和患者护理的潜在影响.
- 解决供应链漏洞需要战略规划,而不仅仅是立即的贸易政策调整.
相关概念视频
01:29Therapeutic Drug Monitoring: Affecting Factors
189
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
189
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
162
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
162
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
141
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
141
01:24Dosage Regimen: Individualization
160
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
160
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
141
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
141
01:28Dosage Regimens: Designs and Approaches
248
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
248